Abstract
ABSTRACTIntroductionIntrinsic hepatic metabolic clearance (CLint) measured with human hepatocytes, apparent intestinal permeability (Papp) obtained using the Caco-2 model, unbound fraction in plasma (fu) and blood-to-plasma concentration ratio (Cbl/Cpl) are commonly used for predicting the hepatic clearance (CLH) and oral bioavailability (F) of drug candidates in humans. The primary objective was to select drugs whosein vitrohepatocyte CLint, Caco-2 Papp, fuand Cbl/Cplhave been measured in various laboratories and studies, and estimate correlation coefficients (R2) for predicted and observed F and log plasma CLH. Secondary aims were to estimate the laboratory/study variability and its impact on predictions and to compare results toin silicoand animal model-based predictions.Materials and MethodsA literature search was done in order to find unbound hepatocyte CLint, (and corresponding predictedin vivoCLint), Caco-2 Papp, fuand Cbl/Cpldata. Compounds with multiple measurements for the four assays, without significantin vivosolubility/dissolution limitations and with knownin vivoCLHand F, were selected. Min, max and mean estimates were used in the analysis.Results and DiscussionThirty-two compounds with data (in total 561 estimates) produced by 21 major pharmaceutical companies and universities met the inclusion criteria. The predicted vs observed R2for log mean CLint, log mean CLHand mean F were 0.32, 0.08 and 0.20, respectively. Exclusion of atenolol increased the R2for CLHto 0.20. R2-values were considerably lower than those presented in many studies, which seems to be explained by selection bias (choosing favorable reference values). There was considerable interstudy variability for measured and predicted CLint(80- and 1,476-fold mean and max differences, respectively) and measured fu(6.6- and 50-fold mean and max differences, respectively). For F, higher predictive performance was found forin silico(Q2=0.58; head-to-head) and animalin vivomodels (R2=0.30).ConclusionThe combination of data from many laboratories and the use of mean values resulted in reduced selection bias and predictive accuracy. Overall, the predictive accuracy (here R2) for log CLint, log CLHand F was low to moderately low (0.08-0.32). The halved R2compared to individual studies where high performance was demonstrated seems to be explained be selection bias (enabled by large data variability). Animalin vivomodels, and in particular,in silicomethodology, outperformedin vitromethodology for the prediction of F in man.
Publisher
Cold Spring Harbor Laboratory
Reference38 articles.
1. Albaugh DR , Fullenwider CL , Hoelscher S , Freeman KM , Smith CM , Whisnant R , Ferguson SS . 2012. Optimization of a plated cryopreserved human hepatocyte model for assessment of the metabolic stability of low clearance compounds using dextrometorphan, midazolam, tolbutamide, and theophylline. Conference paper in Drug Met Rev. 44.
2. Interlaboratory variability in human hepatocyte intrinsic clearance values and trends with physicochemical properties;Pharm Res,2019
3. Comparison between lab variability and in silico prediction errors for the unbound fraction of drugs in human plasma;Xenobiot,2021
4. Advances in predictions of oral bioavailability of candidate drugs in man with new machine learning methodology;Molecules,2021
5. Fagerholm U. An analysis of laboratory variability and thresholds for human in vitro ADME/PK methods. bioRxiv, Sept. 2022.